An immunotherapeutic drug called BO-112Developed in Spain, it has proven effective in treating various types cancer in the first phase of Phase I trials. The purpose of the study, in which 28 patients with solid tumors – including lung cancer, kidney cancer and melanoma – participated, was to verify the safety and efficacy of this molecule, both at individual level, as in combination with anti-PD-1 antibodies in patients who did not had responded to these drugs.
The research in which Gregorio Marañón Hospital, Clínica de Navarra and Ramón y Cajal Hospital have participated and which has been presented at the European Congress of Medical Oncology in Munich, revealed that this immunotherapy where BO-112 has been combined with anti-PD1 antibodies (nivolumab or pembrolizumab), it managed to control the disease in 58% of patients and reduce the tumor size in 17% of cases without causing serious side effects.
The new immunotherapy combines the experimental molecule BO-112 with anti PD1 antibodies (nivolumab or pembrolizumab)
An intratumoral therapy
This drug is administered intratumorally, that is, it is injected directly into the tumor lesion so that, as explained by oncology specialist Gregorio Marañón Iván Márquez Rodas, it provokes a response to the tumor and also proinflammatory so that the system immune recognizes the tumor and triggers the immune response.
The anticancer molecule in the experimental phase BO-112, which has just demonstrated its potential to fight resistant cancer – between 30 and 50% of patients treated with PD1 antibodies, does not show a positive response to them – It was discovered in 2008 and the researchers will continue to study its safety profile and action queries and will also test whether it is effective in other types of tumors.
Although the results are hopeful, the experts point out that they are still preliminary, so they need to be confirmed in new studies, and therefore seven Spanish hospitals are responsible for recruiting new patients who have not worked with PD1.